Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373561 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL1866150 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL28133606 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL7981835 | 0.93 | CHRNA1 (0.69) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL9408645 | 0.93 | CHRNA1 (0.69) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL9408589 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL10738344 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL10738351 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL9408584 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 | |
| SCHEMBL28402275 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2CHRNA1CHRNA3CHRNA7CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106966986-B | N- benzyl heterocyclic nitro ketene semiamine analog derivative and synthetic method and antitumor application thereof | 云南大学 | 2019-10-11 | — | — | CN | disclosed |
| CN-105557709-B | Purposes of eight yuan of oxygen bridge heterocyclic compounds as insecticidal synergist | 南京农业大学 | 2018-08-14 | — | — | CN | disclosed |
| CN-106966986-A | N benzyls heterocyclic nitro ketene semiamine analog derivative and synthetic method and antitumor application thereof | 云南大学 | 2017-07-21 | — | — | CN | disclosed |
| CN-105557709-A | Application of eight-membered oxygen-bridge heterocyclic compound as pesticide synergist | UNIV NANJING AGRICULTURAL | 2016-05-11 | — | — | CN | disclosed |
| CN-102596951-B | Heterocyclic sulfonamide derivatives useful as MEK inhibitors | NOVARTIS AG | 2015-04-15 | — | — | CN | disclosed |
| EP-2496575-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| EP-2496575-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | Novartis AG (CH) | 2012-09-12 | — | — | EP | disclosed |
| CN-102596951-A | Heterocyclic sulfonamide derivatives useful as mek inhibitors | NOVARTIS AG | 2012-07-18 | — | — | CN | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| WO-2011054828-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-0623601-A1 | N-(3-Fluorobenzyl)heterocyclic derivatives and their use as pesticides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | BRAF, KSR2, NRAS | SMN1; SMN2 3656/4885CHRNA1 4536/4885CHRNA3 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.